Thyroid Cancer is malignant disease arising from cells of the thyroid gland, an endocrine organ in the front of the neck that produces hormones involved in regulation of metabolism and other physiological processes. The principal differentiated thyroid cancers are papillary and follicular thyroid carcinoma, which arise from follicular cells and generally retain some features of normal thyroid biology. Other important types include medullary thyroid carcinoma, which arises from parafollicular C cells, and anaplastic thyroid carcinoma, an uncommon but highly aggressive tumour. These cancers differ markedly in molecular biology, clinical behaviour, treatment and prognosis, so "Thyroid Cancer" is a broad diagnostic category rather than one uniform disease.
Papillary thyroid carcinoma is the most common thyroid cancer and frequently has a favourable prognosis, although some tumours can behave aggressively. Follicular thyroid carcinoma differs from papillary carcinoma in its characteristic routes of spread and pathological criteria, with vascular invasion being particularly important in classification. Medullary thyroid carcinoma originates from C cells and can occur sporadically or as part of inherited syndromes involving pathogenic variants in the RET gene, including multiple endocrine neoplasia type 2. Anaplastic thyroid carcinoma is rare but typically grows rapidly and can compromise structures in the neck. These distinctions are essential because treatments effective for differentiated thyroid cancers may not be appropriate for all thyroid tumour types.
Risk factors for Thyroid Cancer include exposure to ionising radiation, particularly during childhood, certain inherited genetic conditions and some demographic and environmental factors. A history of therapeutic radiation involving the head or neck can increase risk, while many thyroid cancers occur without a clearly identifiable cause. Family history is especially relevant in medullary thyroid carcinoma because inherited RET alterations can substantially alter risk and may have implications for relatives. The presence of a thyroid nodule is common and most thyroid nodules are not malignant, so a palpable or radiologically detected nodule should not automatically be interpreted as cancer.
Thyroid Cancer can present as a thyroid nodule or neck swelling, although many cancers are discovered incidentally during imaging performed for another reason. Other possible features include hoarseness, difficulty swallowing, a sensation of neck pressure or enlarged cervical lymph nodes. Symptoms often reflect the location or size of the tumour rather than the production of thyroid hormones. Most thyroid cancers do not cause hyperthyroidism or hypothyroidism at presentation, so a normal thyroid-function test does not by itself exclude cancer. A rapidly enlarging neck mass, vocal-cord dysfunction or significant swallowing or breathing difficulty requires prompt clinical assessment because these findings can indicate local invasion or another significant process.
Evaluation of suspected Thyroid Cancer generally involves clinical assessment, thyroid-function testing where appropriate, ultrasound of the thyroid and neck, and fine-needle aspiration of selected nodules according to ultrasound and clinical risk features. Ultrasound can characterise nodule composition, margins, calcification, vascularity and associated lymph nodes. Cytology from fine-needle aspiration can classify many nodules, although some follicular-pattern lesions cannot be definitively distinguished as benign or malignant by cytology alone because invasion must be assessed histologically. Molecular testing may provide additional information in selected indeterminate cases. Diagnosis therefore integrates imaging, cytology, histology and clinical context.
Treatment depends strongly on tumour type and risk. Surgery is central to management of many differentiated thyroid cancers and may involve removal of part or all of the thyroid, with lymph-node surgery when clinically indicated. Radioactive iodine can be used for selected differentiated cancers because some thyroid cells retain the ability to concentrate iodine. Thyroid hormone treatment can both replace normal hormone production after surgery and, in selected patients, suppress thyroid-stimulating hormone to reduce stimulation of residual differentiated thyroid cancer. Advanced disease may require targeted therapies or other systemic treatments. The appropriate extent of treatment has become increasingly risk-adapted because some small, low-risk cancers may behave indolently.
Thyroid Cancer can spread to regional lymph nodes and, in more advanced cases, to distant sites including the lungs and bones. Prognosis depends on histological type, age, tumour size, local invasion, lymph-node involvement, distant spread and molecular characteristics. Some differentiated thyroid cancers can be monitored or treated successfully over long periods, while anaplastic thyroid carcinoma has a substantially different clinical course. Follow-up can include clinical examination, thyroid-function testing, thyroglobulin measurement in appropriate differentiated-cancer settings and imaging. Persistent or recurrent disease can require additional surgery, radioactive iodine, external radiotherapy or systemic therapy depending on tumour characteristics.
Thyroid Cancer should be distinguished from benign thyroid nodules, thyroiditis and non-cancerous enlargement. It is also important not to assume that every thyroid cancer requires immediate extensive treatment; management increasingly considers tumour risk, patient factors and the potential harms of intervention. Conversely, an apparently small lesion can occasionally have biologically important features that warrant treatment. Advances in molecular classification, targeted therapy, imaging and risk stratification continue to change practice. The overall clinical approach therefore combines careful assessment of thyroid and neck abnormalities with pathology-based classification and proportionate treatment rather than treating all thyroid nodules or cancers as biologically equivalent.
